The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase III trial of mFOLFOX7 or CapeOX plus bevacizumab versus 5-FU/l-LV or capecitabine plus bevacizumab as initial therapy in elderly patients with metastatic colorectal cancer: JCOG1018 study (RESPECT).
 
Tetsuya Hamaguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Fujifilm; Lilly; Merck Serono; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Junki Mizusawa
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Yasuhiro Shimada
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
Research Funding - MSD K.K (Inst); Taiho Pharmaceutical (Inst)
 
Fumio Nagashima
Speakers' Bureau - Chugai Pharma; Janssen; Kyowa Hakko Kirin; Merck Serono; Ono Pharmaceutical; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Masahiko Ando
Consulting or Advisory Role - Asahi Kasei
Research Funding - Kyowa Kirin (Inst)
 
Hitoshi Ojima
No Relationships to Disclose
 
Tadamichi Denda
Honoraria - Sawai Pharmaceutical Co
Speakers' Bureau - Ono Pharmaceutical; Sysmex
Research Funding - DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Jun Watanabe
Speakers' Bureau - Covidien; Johnson & Johnson/Janssen; Lilly Japan
 
Katsunori Shinozaki
Honoraria - Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Merck; Mochida Pharmaceutical Co. Ltd.; Nihonkayaku; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Takeda
 
Hideo Baba
Honoraria - Taiho Pharmaceutical
Research Funding - Asahi Kasei; Chugai Pharma (Inst); Johnson & Johnson K.K.; Lilly Japan; MSD K.K (Inst); Shin Nippon Biomedical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Masako Asayama
Honoraria - Bayer; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Isofol Medical (Inst); Takeda (Inst)
 
Tadao Fukushima
No Relationships to Disclose
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Ken Nakata
No Relationships to Disclose
 
Shunsuke Tsukamoto
No Relationships to Disclose
 
Hiroshi Katayama
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - Bayer Yakuhin; Chugai Pharma; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyorin (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Haruhiko Fukuda
Honoraria - Chugai Pharma
 
Yukihide Kanemitsu
No Relationships to Disclose